The Authors Reply:  by Perkins, Bruce A. et al.
Comments on ‘In patients with
type 1 diabetes and new-onset
microalbuminuria the
development of advanced chronic
kidney disease may not require
progression to proteinuria’
To the Editor: Recently, Perkins et al.1 reported that in
patients with type 1 diabetes (DM1) and new-onset of
microalbuminuria (MAU) glomerular ﬁltration rate (eGFR-
MDRD) began to decline even before the development of
proteinuria.
We sought to study diabetic nephropathy and cardiomyo-
pathy in 78 asymptomatic, normotensive patients with well-
controlled type 2 diabetes (DM2)—hemoglobin A1co7%,
duration up to 15 months. The lipid proﬁle, inﬂammation,
homocysteine, NT-proBNP, eGFR (MDRD), and MAU were
determined. High-resolution transthoracic echocardiography
and exercise stress-echocardiography were used for the
assessment of left ventricular dysfunction (LVD—diastolic
dysfunction and silent ischemia).
None of the patients had MAU. GFR490ml per min per
1.73m2 was found in 17 (25%) patients, 13 had eGFR
between 60 and 69.9ml per min per 1.73m2, and six (9%)
had eGFR o60ml per min per 1.73m2. LVD was revealed in
10 patients. Patients with eGFR o69.9ml per min per
1.73m2 were older than those with normal eGFR. The former
had also the lowest NT-proBNP. Negative correlation was
found between GFR and patient age, sex, hemoglobin A1c,
LVD, but LVD correlated positively with NT-proBNP.
Multiple linear regression analysis revealed positive associa-
tions between eGFR and patient sex, age (Po0.01–0.002),
apolipoprotein A (P¼ 0.037), but negative with LVD
(P¼ 0.019).
The results conﬁrmed previously reported data that in
patients with DM11 and also in those with DM2,2 MAU is not
a reliable surrogate marker for declining kidney function.
Impaired kidney function was found frequently in asympto-
matic, normotensive, non-albuminuric patients with well-
controlled DM2 and, in addition, 14.5% of the patients had
diastolic dysfunction and silent ischemia.
1. Perkins BA, Ficociello LH, Roshan B et al. In patients with type 1 diabetes
and new-onset microalbuminuria the development of advanced chronic
kidney disease may not require progression to proteinuria. Kidney Int 2009;
77: 57–64.
2. Macisaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbuminuric
renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27:
195–200.
Jelena S. Mitrovic1 and Visnja Lezaic2
1Department of Endocrinology, Clinical Centre of Serbia, School of Medicine,
Belgrade, Serbia and 2Department of Nephrology, Clinical Center of Serbia,
School of Medicine, Belgrade, Serbia
Correspondence: Visnja Lezaic, Department of Nephrology, Clinical
Centre of Serbia, Pasterova 2, Beograd 11 000, Serbia.
E-mail: visnjalezaic@gmail.com
Kidney International (2010) 78, 1049; doi:10.1038/ki.2010.300
The Authors Reply: We appreciate the interest taken in our
article.1 Mitrovic and Lezaic2 observed in cross-sectional
analysis that a subset with short diabetes duration had stage
III chronic kidney disease despite normoalbuminuria. Although
this could be explained by technical limitations in GFR
determined by the Modiﬁcation of Diet in Renal Disease Study
formula and urinary albumin excretion estimation, or by
concomitant renin–angiotensin system blockade, it raises a
fundamentally important question: Do individuals with nor-
moalbuminuria and stage III chronic kidney disease represent
the extremes of a normal distribution, who will have stable (but
low) renal function, or does the low GFR indicate risk for
progressive GFR loss despite the lack of proteinuria?
We aimed to answer this question through the longitudinal
study of our First Joslin Kidney Study in type 1 diabetes (1990
to present). Results indicate that those with normoalbumi-
nuria have low risk of progressive GFR loss (even if GFR is
lower), but that the onset of microalbuminuria initiates, in a
third of individuals, a progressive process of early renal
function decline to stage III chronic kidney disease that is not
dependent on subsequent advancement to proteinuria.1,3 The
implication is that the measurement of urinary albumin
excretion alone is insufﬁcient for prognostication—this likely
requires albumin excretion used in combination with a
marker for early renal function decline. Cross-sectional
measurement of GFRMDRD is an insufﬁcient proxy for early
renal function decline. We must improve this aspect of
practice by working to determine the best methods for
identifying early renal function decline when GFR is still in its
normal ranges—perhaps by way of serial cystatin C estima-
tion—and identify the pathophysiological processes that
initiate it and the therapies that attenuate it.
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